CDK9 and gastric cancer: We found the high COX-2 group in GC presented lower drug sensitivity to Gefitinib, Afatinib, Erlotinib, XAV939, AZD1332, Sapitinib, Wnt-C59, CDK9, Ibrutinib, AZD3795, Osimertinib and P22077 (Figure 3D).